Asano Miki, Gundry Steven R, Razzouk Anees J, del Rio Michael J, Thomas Melanie, Chinnock Richard E, Bailey Leonard L
Department of Surgery, Loma Linda University School of Medicine, Loma Linda, California 92350, USA.
Ann Thorac Surg. 2002 Dec;74(6):1979-85. doi: 10.1016/s0003-4975(02)04065-1.
We evaluated the role of total lymphoid irradiation (TLI) in the management of refractory rejection among pediatric heart transplant patients.
Eleven of 298 patients underwent TLI at 6 to 195 months of age and were divided into subgroups: those who survived (group A, n = 7) and those who did not survive beyond 1 year after TLI (group D, n = 4). Non-TLI recipient data were considered as the controls.
Six out of 11 patients died eventually (54%). TLI was initiated 3 to 107 months after transplantation with a dosage of 600 to 840 cGy. The pre-TLI rejection rate (0.62 +/- 0.40 per month) was higher (p < 0.0001); however, the post-TLI rejection rate (0.24 +/- 0.65 per month) showed no significant difference from the control rejection rate. The Cox proportional hazard model found significance for TLI as a risk factor for development of posttransplant coronary artery disease (relative risk, 4.8; 95% CI, 1.1 to 21.3) and posttransplant lymphoproliferative disease (relative risk, 47.9; 95% CI, 1.6 to 1,475.3), respectively. Although the rejection rate decreased after TLI in both groups (group A pre/post, 0.51 +/- 0.31/0.06 +/- 0.08 per month; group D pre/post, 0.82 +/- 0.49/0.57 +/- 1.09 per month), significance was obtained only in group A (p = 0.018).
TLI was an effective adjunct for reversal of refractory rejection in pediatric heart transplantation by reducing the rejection rate. Great care must be taken for the risk of development of coronary artery disease or lymphoproliferative disease.
我们评估了全身淋巴照射(TLI)在小儿心脏移植患者难治性排斥反应管理中的作用。
298例患者中有11例在6至195个月龄时接受了TLI,并分为亚组:存活者(A组,n = 7)和TLI后1年以上未存活者(D组,n = 4)。非TLI受者数据作为对照。
11例患者中有6例最终死亡(54%)。TLI在移植后3至107个月开始,剂量为600至840 cGy。TLI前排斥率(每月0.62±0.40)较高(p < 0.0001);然而,TLI后排斥率(每月0.24±0.65)与对照排斥率无显著差异。Cox比例风险模型发现TLI分别作为移植后冠状动脉疾病(相对风险,4.8;95%可信区间,1.1至21.3)和移植后淋巴细胞增生性疾病(相对风险,47.9;95%可信区间,1.6至1475.3)发生的危险因素具有显著性。尽管两组TLI后排斥率均下降(A组治疗前/后,每月0.51±0.31/0.06±0.08;D组治疗前/后,每月0.82±0.49/0.57±1.09),但仅在A组有显著性差异(p = 0.018)。
TLI通过降低排斥率是小儿心脏移植中逆转难治性排斥反应的有效辅助手段。必须高度警惕冠状动脉疾病或淋巴细胞增生性疾病发生的风险。